Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Burns

Pain Medicine Reno, NV Medical Doctor

NPI 1184745465 CMS profile 1250729

5437 Kietzke Lane, Reno, NV 89511

Open in the dashboard

General payments

$20,438

214 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Burns of Reno, NV is reported in the CMS Open Payments database as having received $20,438 across 214 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $80 3
2024 General $273 6
2023 General $37 2
2022 General $562 32
2021 General $3,280 33
2020 General $8,056 29
2019 General $8,149 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Burns
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Jonathan Burns were reported at $80. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Jonathan Burns Pain Medicine median Middle half National median
2019 $8,149 $409 $115–$1,311 $163
2020 $8,056 $214 $66–$666 $114
2021 $3,280 $299 $84–$899 $132
2022 $562 $335 $103–$1,149 $149
2023 $37 $376 $114–$1,228 $160
2024 $273 $387 $115–$1,173 $164
2025 $80 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $14,686 114 payments
  2. Medtronic USA, Inc. $2,504 26 payments
  3. Vertiflex, Inc. $1,627 15 payments
  4. Medtronic, Inc. $574 11 payments
  5. Stimwave Technologies Incorporated $455 5 payments
  6. Nevro Corp. $280 29 payments
  7. Radius Health, Inc. $87 1 payment
  8. Biohaven Pharmaceutical Holding Company Ltd. $81 4 payments
  9. Amgen Inc. $33 2 payments
  10. Sun Pharmaceutical Industries Inc. $27 1 payment
  11. Other $86 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,800 9 payments
  2. Food and Beverage $4,845 187 payments
  3. Travel and Lodging $4,792 18 payments
Products named General payments · program years 2019–2025
  1. SPECTRA WAVEWRITER $10,460 23 payments
  2. WAVEWRITER ALPHA $2,448 8 payments
  3. SYNCHROMED $2,246 20 payments
  4. Superion ISS $1,627 15 payments
  5. General - Therapies $600 1 payment
  6. GENERAL PAIN MANAGEMENT $512 19 payments
  7. StimQ Freedom-4A Receiver Kit Channel A US w/ Receiver $328 2 payments
  8. StimQ Receiver Stimulator Kit Channel A US w/Receiver $328 2 payments
  9. Freedom-4A Receiver Kit Channel A US w/ Receiver $328 2 payments
  10. Freedom-8A Receiver Kit Channel A US w/ Receiver $328 2 payments
  11. Other $2,568 130 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

82

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$610

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

0%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tamsulosin Hcl Generic 14 $174
Atorvastatin Calcium Generic 22 $144
Gabapentin Generic 15 $137
Losartan Potassium Generic 17 $94
Amlodipine Besylate Generic 14 $61

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$292,572

Medicare's payments for the services billed

Medicare patients

963

Average age 73

Services billed

4,843

476 women, 487 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 37%
Ischemic heart disease 33%
Depression 29%
Chronic kidney disease 27%
Atrial fibrillation 23%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

214 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record